Hereditary Transthyretin-mediated Amyloidosis Masquerading as Diabetic Neuropathy and Lumbar Radiculopathy

被引：0
|
作者：
Horiuchi, K. [1 ]
Hortelano, C. [2 ]
Fogel, J. [2 ]
机构：
[1] Icahn Sch Med Mt Sinai, Dept Med, Mt Sinai Beth Israel, New York, NY USA
[2] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY USA
来源：
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY | 2024年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
C15
引用
收藏
页码：S187 / S187
页数：1
相关论文
共 50 条
  • [21] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
    Gonzalez-Duarte, Alejandra
    Judge, Daniel P.
    Dispenzieri, Angela
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Polydefkis, Michael
    NEUROLOGY, 2020, 94 (15)
  • [22] NEUROPATHY PHENOTYPE IN HEREDITARY TRANSTHYRETIN AMYLOIDOSIS
    Carr, Aisling
    Pelayo, Ana
    Wechalekar, A. D.
    Whelan, C. J.
    Gilmore, J. D.
    Hawkins, P. N.
    Reilly, M. M.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (10):
  • [23] Neurofilament light chain (NfL) as a potential biomarker in hereditary transthyretin-mediated (hATTR) amyloidosis
    Ticau, Simina
    Sridharan, Gautham
    Tsour, Shira
    Cantley, William
    Vaishnaw, Akshay
    Nioi, Paul
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 : S13 - S13
  • [24] Impact of Patisiran, an RNAi Therapeutic, on Diarrhea Symptoms in Patients With Hereditary Transthyretin-Mediated Amyloidosis
    Obici, Laura
    Gonzalez-Duarte, Alejandra
    Waddington-Cruz, Marcia
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Ueda, Mitsuharu
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1657 - S1657
  • [25] Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gorevic, Peter
    Franklin, Jaclyn
    Chen, Jihong
    Sajeev, Gautam
    Wang, Jessie C. H.
    Lin, Hollis
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (01) : 121 - 129
  • [26] Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progression
    Adams, David
    Algalarrondo, Vincent
    Polydefkis, Michael
    Sarswat, Nitasha
    Slama, Michel S.
    Nativi-Nicolau, Jose
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [27] Patisiran for the Treatment of Transthyretin-mediated Amyloidosis with Cardiomyopathy
    Ioannou, Adam
    Fontana, Marianna
    Gillmore, Julian D.
    HEART INTERNATIONAL, 2023, 17 (01): : 27 - 35
  • [28] Patient experience in a rare disease: application of the IEXPAC questionnaire in hereditary transthyretin-mediated amyloidosis
    Pelaez Bejarano, Ana
    de las Aguas Robustillo Cortes, Maria
    Guzman Ramos, Maria Isabel
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (06): : 175 - 180
  • [29] Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients with Hereditary Transthyretin-Mediated Amyloidosis
    Judge, Daniel P.
    Gonzalez-Duarte, Alejandra
    Dispenzieri, Angela
    Lin, Hollis
    Merkel, Madeline
    Wang, Yue
    Polydefkis, Michael
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S78 - S78
  • [30] Neurofilament Light Chain (NfL) as a Potential Biomarker in Hereditary Transthyretin-Mediated (hATTR) Amyloidosis
    Nioi, Paul
    Ticau, Simina
    Sridharan, Gautham
    Tsour, Shira
    Cantley, William
    Chan, Amy
    Gilbert, Jason
    Erbe, David
    Fitzgerald, Kevin
    NEUROLOGY, 2020, 94 (15)
12345